

# In-vivo tracking of $^{19}\text{F}$ -labeled natural killer cells with MRI in lymphoid tumor model

Kai D. Ludwig<sup>1</sup>, Jeremy W. Gordon<sup>1</sup>, Myriam N. Bouchlaka<sup>2</sup>, Christian M. Capitini<sup>2</sup>, Bryan P. Bednarz<sup>1,3</sup>, and Sean B. Fain<sup>1,3</sup>

<sup>1</sup>Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, United States, <sup>2</sup>Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, United States,

<sup>3</sup>Radiology, University of Wisconsin-Madison, Madison, Wisconsin, United States

**Target Audience:** Researchers and clinicians interested in immunotherapeutic cell-tracking with  $^{19}\text{F}$  MRI.


**Purpose:** Tumor-specific immunotherapy is emerging as a novel treatment paradigm for patients with metastatic tumors incurable with conventional therapies. Natural killer (NK) cells are important innate immune effector cells shown to have anti-tumor effects against hematological and non-hematological cancers [1-3]. Often, lack of knowledge on trafficking patterns and NK cell biology limits the efficacy of adoptively transferred NK cell's anti-tumor response and clinically-approved reagents are not yet available. Labeling of various immune cells in-vivo with fluorinated compounds has allowed for detection and cell-tracking via  $^{19}\text{F}$  MRI [4-5], but to date NK cells have not been studied with this approach. The goals of this study are to determine the trafficking pattern of  $^{19}\text{F}$ -labeled NK cells in-vivo and how they mediate their anti-tumor effects in a humanized mouse model of pediatric cancers.

**Methods: Animals:** Two healthy mice and one lymphoma tumor-bearing mouse were used for this study. Mice were anesthetized with either 1.5% isoflurane (Iso) or ketamine/xylazine (Ket/Xyla) (2mg/10g Ket, 0.2mg/10g Xyla), monitored with a respiration pad and maintained at 36°C using a warm-air blower. **Cells:** Human NK (hNK) and mouse NK cells isolated from healthy donor peripheral blood mononuclear cells were cultured ex-vivo for 2 weeks. Mouse NK cells were initially used due to ease of availability. NK cells were incubated for 24 hours in a commercially available perfluoropolyether (PFPE) tracer agent (Celsense Inc., Pittsburgh PA). hNK cells were subsequently washed and injected intravenously into immunodeficient mice. **MR:** NMR was performed on a 9.4T Varian UI-400 (Agilent Technologies, Santa Clara, CA) spectrometer to verify successful uptake of the PFPE agent into NK cells. Imaging was performed on a 4.7T Varian small animal MRI system using a volume quadrature coil tunable to  $^{19}\text{F}$  (187.9MHz). Coronal  $^{19}\text{F}$  images were acquired using a spin-echo sequence (1.1x1.1mm<sup>2</sup> in-plane resolution, 2mm slice thickness, 16 echoes, 40 averages, ~42 minutes total scan time). A  $^{19}\text{F}$  reference vial (2.3·10<sup>16</sup>  $^{19}\text{F}$  spins/mm<sup>3</sup>) was placed contralateral to the tumor for in-vivo quantification. T<sub>1</sub>-weighted GRE  $^1\text{H}$  images were also acquired to visualize anatomy.


**Results and Discussion:** A dose-dependent response of  $^{19}\text{F}$  signal was shown in mouse NK cells in duplicate (**Fig. 1**). NMR spectra of the separated cells and its supernatant confirmed that  $^{19}\text{F}$  signal originated from within the hNK cells, rather than the supernatant (**Fig. 2**).  $^{19}\text{F}$ -labeled hNK cells were then injected into an immune deficient mouse and  $^{19}\text{F}$  signal accumulation was noted intra-tumor and on the periphery of the tumor (arrows in **Fig. 3**). However,  $^{19}\text{F}$  background signal contamination was observed (arrowheads in **Fig. 3**) due to Iso anesthesia. Iso was compared to Ket/Xyla to determine the extent to which Iso impeded interpretation of  $^{19}\text{F}$  images. The results point to a strong background  $^{19}\text{F}$  signal from Iso contamination (**Fig. 4**).

**Conclusions:**  $^{19}\text{F}$  labeling of natural killer cells has been confirmed in-vitro, both with imaging and spectroscopic analysis. hNK infusion into a lymphoid tumor-bearing mouse showed that hNK cells can be successfully detected in-vivo, but there is some variance in the  $^{19}\text{F}$  signal in the region of tumor. Given confounding fluorine signal contamination from Iso gas anesthesia, future studies will utilize Ket/Xyla anesthesia to eliminate background fluorine. NK cells can be labeled with  $^{19}\text{F}$  and detected in-vitro and in-vivo, but background fluorine signals can interfere with detection by MRI.


**References:** [1] Miller et al. *Blood*. 2005. 105(8):3051-3057. [2] Ruggeri et al. *Science*. 2002. 295(5562):2097-100. [3] Murphy et al. *Imm. Rev.* 2001. 181(1): 279-289. [4] Srinivas et al. *MRM*. 2007. 58:725-734. [5] Helfer et al. *Cytotherapy*. 2010. 12:238-250.




**Fig. 1:** MR images showing dose-dependent signal of  $^{19}\text{F}$ -labeled mouse NK cells.



**Fig. 2:**  $^{19}\text{F}$  NMR spectroscopy of PFPE in (left) supernatant of hNK cells, and (right) hNK cells post-washing and lysis.



**Fig. 3:**  $^{19}\text{F}$  signal in a lymphoid tumor (arrows) bearing mouse 24 hours (left) and 48 hours (right) following hNK injection.  $^{19}\text{F}$  signal contamination noted (arrowheads).



**Fig. 4:**  $^{19}\text{F}$  signal in mice anesthetized with (L) Iso and (R) Ket.